Kazuo Kasahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuo Kasahara has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Takashi Sone
Department of Respiratory Medicine, Kanazawa University Hospital
5 shared publications- Akihito Okazaki
Department of Respiratory Medicine Kaga Medical Center Kaga Ishikawa Japan
4 shared publications - Hideharu Kimura
Department of Respiratory Medicine, Kanazawa University Hospital
4 shared publications - Noriyuki Ohkura
Department of Respiratory Medicine, Kanazawa University Hospital, Ishikawa, Japan
4 shared publications - Johsuke Hara
Department of Respiratory Medicine, Kanazawa University Hospital, Ishikawa, Japan
3 shared publications - Kazuhiko Shibata
Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Japan
3 shared publications
Latest Publications
- 30 November 2023
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 29 (2) , 115-123
Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy
Background Baseline tumor size (BTS) is one of the prognostic factors of advanced non-small cell lung cancer (NSCLC) treated with immunotherapy. However, its prognostic value in patients with locally advanced NSCLC receiving durvalumab maintenance therapy remains unclear. Methods The present study retrospectively reviewed 136 patients with unresectable stage III NSCLC who underwent CRT and durvalumab at two institutions in Japan. The maximum diameter of the target lesion (max BTS) before CRT was measured, the best response to CRT before durvalumab was evaluated, and the impact of the response on durvalumab was explored. Progression-free survival (PFS) and overall survival (OS) were defined as the time from the day of starting durvalumab. Results Of the total cohort, 133 (97.8%) patients had at least one measurable lesion. The best response to CRT resulting in CR, PR, and SD was seen in 0 (0%), 69 (51.9%), and 64 (48.1%) patients, respectively. PFS was significantly longer in the patients with PR than in those with SD after CRT (median not reached vs. 20.0 months; HR: 0.51; P = 0.023). Moreover, the absence of a massive lesion (max BTS < 50 mm) was associated with a superior CRT response (P < 0.001). Conclusion The best response to induction CRT was associated with better PFS in patients with stage III NSCLC receiving durvalumab following chemoradiotherapy. Although the absence of a massive lesion was associated with a better response to induction CRT in this cohort, this was not translated into PFS and OS benefit.
- 30 November 2023
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 29 (2) , 115-123
Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy
Background Baseline tumor size (BTS) is one of the prognostic factors of advanced non-small cell lung cancer (NSCLC) treated with immunotherapy. However, its prognostic value in patients with locally advanced NSCLC receiving durvalumab maintenance therapy remains unclear. Methods The present study retrospectively reviewed 136 patients with unresectable stage III NSCLC who underwent CRT and durvalumab at two institutions in Japan. The maximum diameter of the target lesion (max BTS) before CRT was measured, the best response to CRT before durvalumab was evaluated, and the impact of the response on durvalumab was explored. Progression-free survival (PFS) and overall survival (OS) were defined as the time from the day of starting durvalumab. Results Of the total cohort, 133 (97.8%) patients had at least one measurable lesion. The best response to CRT resulting in CR, PR, and SD was seen in 0 (0%), 69 (51.9%), and 64 (48.1%) patients, respectively. PFS was significantly longer in the patients with PR than in those with SD after CRT (median not reached vs. 20.0 months; HR: 0.51; P = 0.023). Moreover, the absence of a massive lesion (max BTS < 50 mm) was associated with a superior CRT response (P < 0.001). Conclusion The best response to induction CRT was associated with better PFS in patients with stage III NSCLC receiving durvalumab following chemoradiotherapy. Although the absence of a massive lesion was associated with a better response to induction CRT in this cohort, this was not translated into PFS and OS benefit.
- Open Access
- 20 August 2022
- Published by Japan Lung Cancer Society in Haigan
- Vol. 62 (4) , 335-340
A Case of Advanced Thymic Carcinoma with Diffuse Liver Metastases and Acute Liver Failure Treated with a Combination of Carboplatin and Paclitaxel
背景.胸腺癌は年間10万人あたり0.02人に発症する希少癌であり,診断時点で30%の患者が進行期である.診断時の状態から治療導入に難渋するケースが存在する.症例.44歳,女性.20XX年12月末より上腹部膨満感を自覚し前医を受診した.胸部単純CT検査でびまん性肝腫瘍と高度の肝腫大,及び胸腺腫瘍を指摘され当院紹介となった.PET-CTでは胸腺,肝及び骨にFDGの異常集積を認めた.肝生検は困難であり胸腺よりCTガイド下生検が施行され,胸腺癌が検出された.cT1bN2M1b,stage IVb期(OSS,HEP)と診断された.急速な肝機能の増悪,黄疸や高アンモニア血症の出現及び増悪も認めた.当科転科第4病日よりcarboplatin(AUC=6)とpaclitaxel(100 mg/m2)による併用療法を開始した.1サイクル終了時には肝機能は改善し,原発巣及びびまん性肝腫瘍の急速な縮小を認めた.結論.胸腺癌は予後不良な希少疾患である.進行例に対するエビデンスは乏しく,高度な肝機能障害を伴う症例に対する化学療法の報告も少ない.貴重な症例と考え報告した.
- 20 August 2022
- Published by Japan Lung Cancer Society in Haigan
- Vol. 62 (4) , 335-340
Open AccessA Case of Advanced Thymic Carcinoma with Diffuse Liver Metastases and Acute Liver Failure Treated with a Combination of Carboplatin and Paclitaxel
背景.胸腺癌は年間10万人あたり0.02人に発症する希少癌であり,診断時点で30%の患者が進行期である.診断時の状態から治療導入に難渋するケースが存在する.症例.44歳,女性.20XX年12月末より上腹部膨満感を自覚し前医を受診した.胸部単純CT検査でびまん性肝腫瘍と高度の肝腫大,及び胸腺腫瘍を指摘され当院紹介となった.PET-CTでは胸腺,肝及び骨にFDGの異常集積を認めた.肝生検は困難であり胸腺よりCTガイド下生検が施行され,胸腺癌が検出された.cT1bN2M1b,stage IVb期(OSS,HEP)と診断された.急速な肝機能の増悪,黄疸や高アンモニア血症の出現及び増悪も認めた.当科転科第4病日よりcarboplatin(AUC=6)とpaclitaxel(100 mg/m2)による併用療法を開始した.1サイクル終了時には肝機能は改善し,原発巣及びびまん性肝腫瘍の急速な縮小を認めた.結論.胸腺癌は予後不良な希少疾患である.進行例に対するエビデンスは乏しく,高度な肝機能障害を伴う症例に対する化学療法の報告も少ない.貴重な症例と考え報告した.
- 1 January 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 191, 106689
Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease
- 1 January 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 191, 106689
Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease
- Open Access
- 19 January 2021
- Published by Wiley in Cancer Science
- Vol. 112 (4) , 1534-1544
IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum‐based chemotherapy as first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC). Key eligibility criteria for the phase 3, open‐label, IMpower132 study included age ≥18 y, histologically or cytologically confirmed advanced non‐squamous NSCLC per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status of 0/1, and no prior systemic treatment for stage IV NSCLC. Patients received atezolizumab (1200 mg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) or carboplatin (area under the concentration curve, 6 mg/mL/min) (APP arm) or chemotherapy alone (PP arm). The co‐primary study endpoints were overall survival (OS) and investigator‐assessed progression‐free survival (PFS) per RECIST 1.1 in the intention‐to‐treat population. A subgroup analysis was conducted in Japanese patients. In the Japanese subgroup (n = 101), median OS was 30.8 (95% CI, 24.3 to not estimable) mo in the APP arm (n = 48) and 22.2 (95% CI, 15.7‐30.8) mo in the PP arm (n = 53; hazard ratio [HR], 0.63 [95% CI, 0.36‐1.14]). PFS was 12.8 (95% CI, 8.6‐16.6) mo in the APP arm vs 4.5 (95% CI, 4.1‐6.7) mo in the PP arm (HR, 0.33 [95% CI, 0.21‐0.58]). Grade 3/4 treatment‐related adverse events (TRAEs) occurred in 68.8% of APP arm patients and 44.2% of PP arm patients. Consistent with global study results, atezolizumab plus pemetrexed and platinum‐based chemotherapy improved efficacy and was well tolerated in Japanese patients with advanced NSCLC despite a higher incidence of grade 3/4 TRAEs.
- 19 January 2021
- Published by Wiley in Cancer Science
- Vol. 112 (4) , 1534-1544
Open AccessIMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum‐based chemotherapy as first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC). Key eligibility criteria for the phase 3, open‐label, IMpower132 study included age ≥18 y, histologically or cytologically confirmed advanced non‐squamous NSCLC per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status of 0/1, and no prior systemic treatment for stage IV NSCLC. Patients received atezolizumab (1200 mg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) or carboplatin (area under the concentration curve, 6 mg/mL/min) (APP arm) or chemotherapy alone (PP arm). The co‐primary study endpoints were overall survival (OS) and investigator‐assessed progression‐free survival (PFS) per RECIST 1.1 in the intention‐to‐treat population. A subgroup analysis was conducted in Japanese patients. In the Japanese subgroup (n = 101), median OS was 30.8 (95% CI, 24.3 to not estimable) mo in the APP arm (n = 48) and 22.2 (95% CI, 15.7‐30.8) mo in the PP arm (n = 53; hazard ratio [HR], 0.63 [95% CI, 0.36‐1.14]). PFS was 12.8 (95% CI, 8.6‐16.6) mo in the APP arm vs 4.5 (95% CI, 4.1‐6.7) mo in the PP arm (HR, 0.33 [95% CI, 0.21‐0.58]). Grade 3/4 treatment‐related adverse events (TRAEs) occurred in 68.8% of APP arm patients and 44.2% of PP arm patients. Consistent with global study results, atezolizumab plus pemetrexed and platinum‐based chemotherapy improved efficacy and was well tolerated in Japanese patients with advanced NSCLC despite a higher incidence of grade 3/4 TRAEs.
- 1 October 2020
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 64, 101962
Methacholine-induced cough as an indicator of bronchodilator-responsive cough
- 1 October 2020
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 64, 101962
Methacholine-induced cough as an indicator of bronchodilator-responsive cough
- Open Access
- 28 April 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (6) , 2017-2018
Multiple fungus balls in rheumatoid arthritis–associated honeycomb lung
- 28 April 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (6) , 2017-2018
Open AccessMultiple fungus balls in rheumatoid arthritis–associated honeycomb lung
- 19 March 2020
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 21 (2) , 75-79
Histopathological Type of Lung Cancer and Underlying Driver Mutations in Patients with Chronic Obstructive Pulmonary Disease (COPD) versus Patients with Asthma and COPD Overlap: A Single-Center Retrospective Study
Turkthoracj, Turkish Thoracic Journal
- 19 March 2020
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 21 (2) , 75-79
Histopathological Type of Lung Cancer and Underlying Driver Mutations in Patients with Chronic Obstructive Pulmonary Disease (COPD) versus Patients with Asthma and COPD Overlap: A Single-Center Retrospective Study
Turkthoracj, Turkish Thoracic Journal
- 1 July 2019
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 221 (1) , 71-72
Pseudo–Meigs syndrome caused by cancer of the uterine corpus
- 1 July 2019
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 221 (1) , 71-72
Pseudo–Meigs syndrome caused by cancer of the uterine corpus
- 28 May 2019
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 49 (7) , 687-690
Curative thoraco-systemic therapy plus local treatment to the brain for extensive disease-small-cell lung cancer with metastasis only to the brain
We reviewed 11 cases of extensive disease (ED)-SCLC and metastasis only to the brain treated during 2011–14. All patients underwent definitive therapy similar to that for limited disease (LD), combined with local treatment for BM. We compared the survival outcomes of these patients to those of patients with LD (n = 29) or other ED (n = 38) during the same period. Three patients had progression of BM at completion of chemotherapy. Ten patients received whole-brain radiotherapy (4 prophylactic, 6 therapeutic), and remaining one elderly patient underwent stereotactic radiosurgery. Finally, 8 and 3 patients achieved a CR or PR of BM, respectively. Five remained free of progression for 21.1–73.2 months. The progression-free and overall survival outcomes of ED-SCLC with brain only metastases were comparable to those of LD and superior to those of other ED. In conclusion, ED-SCLC with metastasis limited to the brain could be treated with curative intent.
- 28 May 2019
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 49 (7) , 687-690
Curative thoraco-systemic therapy plus local treatment to the brain for extensive disease-small-cell lung cancer with metastasis only to the brain
We reviewed 11 cases of extensive disease (ED)-SCLC and metastasis only to the brain treated during 2011–14. All patients underwent definitive therapy similar to that for limited disease (LD), combined with local treatment for BM. We compared the survival outcomes of these patients to those of patients with LD (n = 29) or other ED (n = 38) during the same period. Three patients had progression of BM at completion of chemotherapy. Ten patients received whole-brain radiotherapy (4 prophylactic, 6 therapeutic), and remaining one elderly patient underwent stereotactic radiosurgery. Finally, 8 and 3 patients achieved a CR or PR of BM, respectively. Five remained free of progression for 21.1–73.2 months. The progression-free and overall survival outcomes of ED-SCLC with brain only metastases were comparable to those of LD and superior to those of other ED. In conclusion, ED-SCLC with metastasis limited to the brain could be treated with curative intent.
- 1 December 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (12) , e199-e200
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma
- 1 December 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (12) , e199-e200
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma